BOSTON SCIENTIFIC BETTING $100 MIL. ON CVIS INTRAVASCULAR ULTRASOUND POTENTIAL
This article was originally published in The Gray Sheet
Executive SummaryBOSTON SCIENTIFIC BETTING $100 MIL. ON CVIS INTRAVASCULAR ULTRASOUND POTENTIAL; on Aug. 31, the two companies announced an agreement whereby BSC would acquire Cardiovascular Imaging Systems, Inc. in a deal valued at $98.6 mil. Under the terms of the agreement, BSC will pay $10.50 per share for all 8.3 mil. outstanding shares of CVIS and about 30,000 shares of employee stocks to be issued between now and the deal's closing. In addition, BSC will pay $10.50 for each of 980,000 outstanding CVIS stock options that have a total value of $5 mil. when exercised.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.